IRIS Accounts Production v26.1.10.61 09930112 director 1.1.25 31.12.25 31.12.25 false true false false true false iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 09930112 2024-12-31 09930112 2025-12-31 09930112 2025-01-01 2025-12-31 09930112 2023-12-31 09930112 2024-01-01 2024-12-31 09930112 2024-12-31 09930112 ns15:EnglandWales 2025-01-01 2025-12-31 09930112 ns14:PoundSterling 2025-01-01 2025-12-31 09930112 ns10:Director1 2025-01-01 2025-12-31 09930112 ns10:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 09930112 ns10:SmallEntities 2025-01-01 2025-12-31 09930112 ns10:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 09930112 ns10:SmallCompaniesRegimeForDirectorsReport 2025-01-01 2025-12-31 09930112 ns10:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 09930112 ns10:FullAccounts 2025-01-01 2025-12-31 09930112 ns10:RegisteredOffice 2025-01-01 2025-12-31 09930112 ns5:CurrentFinancialInstruments 2025-12-31 09930112 ns5:CurrentFinancialInstruments 2024-12-31 09930112 ns5:ShareCapital 2025-12-31 09930112 ns5:ShareCapital 2024-12-31 09930112 ns5:RetainedEarningsAccumulatedLosses 2025-12-31 09930112 ns5:RetainedEarningsAccumulatedLosses 2024-12-31 09930112 ns5:FurnitureFittings 2024-12-31 09930112 ns5:FurnitureFittings 2025-01-01 2025-12-31 09930112 ns5:FurnitureFittings 2025-12-31 09930112 ns5:FurnitureFittings 2024-12-31 09930112 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-12-31 09930112 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-12-31

REGISTERED NUMBER: 09930112 (England and Wales)

| Unaudited Financial Statements |

| for the Year Ended 31 December 2025 |

| for |

| Theranos Real Estate Limited |

| Theranos Real Estate Limited (Registered number: 09930112) |

Contents of the Financial Statements

for the Year Ended 31 December 2025

Page |

| Company Information | 1 |

| Balance Sheet | 2 |

| Notes to the Financial Statements | 4 |

| Theranos Real Estate Limited |

Company Information

for the Year Ended 31 December 2025

| DIRECTOR: | D Guha

| REGISTERED OFFICE: | Unit 4 72 London Road

| Southampton

| Hampshire

| England

| SO15 2AJ

| REGISTERED NUMBER: | 09930112 (England and Wales)

| ACCOUNTANTS: | RAA Gaglani & Co Ltd

| Suite 15 The Enterprise Centre

| Coxbridge Business Park

| Farnham

| Surrey

| GU10 5EH

| Theranos Real Estate Limited (Registered number: 09930112) |

Balance Sheet

31 December 2025

| 2025 |  | 2024

| Notes | £ | £ |

Fixed assets

Tangible assets | 5 | 2,448 |  | 3,264 |  |

Current assets

Debtors | 6 | 549,912 |  | 278,989 |  |

Cash at bank | 1,327,099 |  | 1,222,667 |  |

1,877,011 |  | 1,501,656 |  |

Creditors: amounts falling due within one year | 7 | (1,444,325 | ) | (1,363,813 | ) |

Net current assets | 432,686 |  | 137,843 |  |

Total assets less current liabilities | 435,134 |  | 141,107 |  |

Capital and reserves

Called up share capital | 1 |  | 1 |  |

Retained earnings | 435,133 |  | 141,106 |  |

Shareholders' funds | 435,134 |  | 141,107 |  |

| Theranos Real Estate Limited (Registered number: 09930112) |

Balance Sheet - continued

31 December 2025

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the director and authorised for issue on 27 July 2026 and were signed by:

D Guha - Director

| Theranos Real Estate Limited (Registered number: 09930112) |

Notes to the Financial Statements

for the Year Ended 31 December 2025

1. | STATUTORY INFORMATION

| Theranos Real Estate Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. | STATEMENT OF COMPLIANCE

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006.

3. | ACCOUNTING POLICIES

| BASIS OF PREPARING THE FINANCIAL STATEMENTS

| The financial statements have been prepared under the historical cost convention.

| These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

| The company's functional and presentational currency is pound sterling.

| SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND KEY ACCOUNTING ESTIMATES

| The principal accounting policies applied in the preparation of these financial statements are set out below.

| These policies have been consistently applied to all the years presented, unless otherwise stated.

| GOING CONCERN

| The financial statements have been prepared on a going concern basis.

| TURNOVER

| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates,value added tax and other sales taxes.

| TANGIBLE FIXED ASSETS

| Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

| Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

| The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

| DEPRECIATION

| Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

| Asset class |  | Depreciation method and rate |  |

| Fixtures & fittings |  | 25% reducing balance basis |  |

| Theranos Real Estate Limited (Registered number: 09930112) |

Notes to the Financial Statements - continued

for the Year Ended 31 December 2025

3. | ACCOUNTING POLICIES - continued

| TAXATION

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| DEFERRED TAX

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| DEFINED CONTRIBUTION PENSION OBLIGATION

| A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

| Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

4. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 4 (2024 - 4 ) .

5. | TANGIBLE FIXED ASSETS

| Fixtures

| and

| fittings

£ |

| COST

| At 1 January 2025

| and 31 December 2025 | 36,445 |  |

| DEPRECIATION

| At 1 January 2025 | 33,181 |  |

| Charge for year | 816 |  |

| At 31 December 2025 | 33,997 |  |

| NET BOOK VALUE

| At 31 December 2025 | 2,448 |  |

| At 31 December 2024 | 3,264 |  |

| Theranos Real Estate Limited (Registered number: 09930112) |

Notes to the Financial Statements - continued

for the Year Ended 31 December 2025

6. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Other debtors | 549,912 |  | 278,989 |  |

7. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade creditors | 15,168 |  | 15,168 |  |

| Corporation tax | 98,281 |  | 44,012 |  |

| VAT | 12,420 |  | 14,106 |  |

| Landlords Control Account | 1,020,753 |  | 1,020,753 |  |

| Directors' current accounts | 297,454 |  | 269,565 |  |

| Accruals and deferred income | 249 |  | 209 |  |

1,444,325 |  | 1,363,813 |  |